Shawn A. Abbasi

Shawn A. Abbasi

Auto-generated profile, based on publicly available information

Shawn A. Abbasi

U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2020 in Science
Verified
Journal Article
Open access
PDF file
KCKui K. Chan
Kui K. Chan
DDDanielle Dorosky
Danielle Dorosky
PSPreeti Sharma
Preeti Sharma
SAShawn A. Abbasi
Shawn A. Abbasi
JDJohn Dye
John Dye
EPErik Procko
Erik Procko
A decoy receptor for SARS-CoV-2: For severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter human cells, the spike protein on the surface of the virus must bind to the host receptor protein, angiotensin-converting enzyme 2 (ACE2). A soluble version of the receptor is being explored as a therapeutic. Chan et al. used deep mutagenesis to identify ACE2 mutants that bind more tightly to the spike protein and combined mutations to further increase binding affinity (see the Perspective by DeKosky). A promising variant was engineered to be a stable dimer that has a binding affinity for the spike protein; it is comparable with neutralizing antibodies and neutralized both SARS-CoV-2 and SARS-CoV-1 in a cell-based assay. In addition, the similarity to the natural receptor may limit the possibility for viral escape. Science , this issue p. 1261 ; see also p. 1167

4 June 2021 in Science
Verified
Journal Article
Open access
PDF file
WVWilliam N. Voss
William N. Voss
YHYixuan J. Hou
Yixuan J. Hou
NJNicole V. Johnson
Nicole V. Johnson
GDGeorge Delidakis
George Delidakis
JKJin Eyun Kim
Jin Eyun Kim
Gregory C. IppolitoGregory C. Ippolito
Gregory C. Ippolito
A public anti-COVID antibody repertoire: Most analyses of the antibody responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have focused on antibodies cloned from memory B cells. This approach has led researchers to conclude that neutralizing antibodies (nAbs) primarily target the receptor-binding domain (RBD) of the virus's spike protein. Voss et al. took a different approach, using proteomic deconvolution of the serum immunoglobulin G antibody repertoire from four COVID-19 convalescent patients. They found that the nAb response was largely directed against epitopes such as the N-terminal domain (NTD), which lie outside the RBD. Several of these nAbs were shared among donors and targeted an NTD epitope that is frequently mutated by variants of concern. Science , abg5268, this issue p. 1108